CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen’s adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.
Reageer